Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Bioconjug Chem ; 30(11): 2982-2988, 2019 11 20.
Artículo en Inglés | MEDLINE | ID: mdl-31671265

RESUMEN

Antibody-drug conjugates (ADCs) are an established modality for the tissue-specific delivery of chemotherapeutics. However, due to the hydrophobic nature of many cytotoxic payloads, challenges remain in developing chemically stable ADCs with high drug loading. In previous studies, payload structure, unique stimuli-responsive chemistries, and PEGylated cross-linkers have been used to decrease ADC hydrophobicity. In this work, we investigate the effect of a new parameter, cross-linker sequence. A support-free synthesis of PEGylated, sequence-defined cross-linkers was developed and applied to the synthesis of three constitutionally isomeric ADCs containing PEG side chains and a monomethyl auristatin E payload. Placement of PEG side chains distally from the payload was found to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency. This work establishes a versatile method for synthesizing multifunctional cross-linkers and identifies cross-linker sequence as a new handle for modulating the performance of ADCs.


Asunto(s)
Anticuerpos Monoclonales/química , Proliferación Celular , Reactivos de Enlaces Cruzados/química , Interacciones Hidrofóbicas e Hidrofílicas , Inmunoconjugados/química , Inmunoconjugados/farmacología , Oligopéptidos/química , Femenino , Humanos , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/inmunología , Neoplasias Ováricas/metabolismo , Neoplasias Ováricas/patología , Receptor ErbB-2/antagonistas & inhibidores , Receptor ErbB-2/inmunología , Células Tumorales Cultivadas
2.
Bioconjug Chem ; 30(9): 2452-2457, 2019 09 18.
Artículo en Inglés | MEDLINE | ID: mdl-31409067

RESUMEN

Site-specific modification of native antibodies has proven advantageous, as it enhances the properties of antibody-based bioconjugates without the need to manipulate the genetic code. However, native antibody modification is typically limited to strategies that introduce a single functional handle. In this work, we addressed this limitation by designing heterobifunctional substrates for microbial transglutaminase (MTG) that contain both azide and methyltetrazine "click" handles. Structure-conjugation relationships for these substrates were evaluated using the Her2-targeted antibody trastuzumab. Förster resonance energy transfer (FRET) was used to demonstrate that these chemical handles are mutually orthogonal. This orthogonality was leveraged for the one-pot synthesis of a bifunctional antibody-drug conjugate (ADC). This ADC, containing a maytansine-derived payload and a hydrophobicity-masking polyethylene glycol (PEG) side chain, demonstrated potent in vitro activity in SKOV3 cells. These studies establish the dual "click" approach as a powerful technique in the toolbox for native antibody modification.


Asunto(s)
Inmunoconjugados/química , Inmunoconjugados/metabolismo , Transglutaminasas/metabolismo , Línea Celular Tumoral , Química Clic , Cisteína/química , Células HEK293 , Humanos , Microbiología , Oxidación-Reducción , Triptófano/química
3.
Bioconjug Chem ; 30(6): 1702-1710, 2019 06 19.
Artículo en Inglés | MEDLINE | ID: mdl-31083974

RESUMEN

Antibody-drug conjugates utilize the antigen specificity of antibodies and the potency of chemotherapeutic and antibiotic drugs for targeted therapy. However, as cancers and bacteria evolve to resist the action of drugs, innovative controlled release methods must be engineered to deliver multidrug cocktails. In this work, we engineer lipoate-acid ligase A (LplA) acceptor peptide (LAP) tags into the constant heavy and light chain of a humanized Her2 targeted antibody, trastuzumab. These engineered LAP tags, along with the glutamine 295 (Q295) residue in the heavy chain, were used to generate orthogonally cleavable site-specific antibody conjugates via a one-pot chemoenzymatic ligation with microbial transglutaminase (mTG) and LplA. We demonstrate orthogonal cargo release from these dual-labeled antibody bioconjugates via matrix metalloproteinase-2 and cathepsin-B-mediated bond cleavage. To the best of our knowledge, this is the first demonstration of temporal control on dual-labeled antibody conjugates, and we believe this platform will allow for sequential release and cooperative drug combinations on a single antibody bioconjugate.


Asunto(s)
Antineoplásicos Inmunológicos/química , Inmunoconjugados/química , Trastuzumab/química , Antineoplásicos Inmunológicos/farmacocinética , Línea Celular Tumoral , Liberación de Fármacos , Humanos , Inmunoconjugados/farmacocinética , Modelos Moleculares , Péptido Sintasas/química , Péptidos/química , Trastuzumab/farmacocinética
4.
Bioconjug Chem ; 28(4): 907-912, 2017 04 19.
Artículo en Inglés | MEDLINE | ID: mdl-28191937

RESUMEN

Cleavable and heteromultifunctional cross-linkers have proven critical in a wide range of biological applications. Traditional approaches for synthesizing these linkers suffer from various synthetic and functional limitations. In this work, an efficient sequence-defined synthetic methodology, developed for the assembly of oligothioetheramides, was used to address many of these limitations. Four heterotrifunctional cross-linkers with up to two orthogonal internal cleavage sites were synthesized. These linkers were conjugated to a pair of fluorophores that undergo Förster resonance energy transfer (FRET) and a model protein-human transferrin. Orthogonal bond cleavage was validated by mass spectrometry, fluorescent gel electrophoresis, and confocal microscopy. These studies demonstrate the versatility and biological utility of oligothioetheramides as a new class of multifunctional chemical cross-linkers and biologically relevant fluorescent probes.


Asunto(s)
Amidas/química , Reactivos de Enlaces Cruzados/química , Colorantes Fluorescentes/química , Transferrina/química , Amidas/síntesis química , Compuestos de Boro/química , Reactivos de Enlaces Cruzados/síntesis química , Éteres/síntesis química , Éteres/química , Transferencia Resonante de Energía de Fluorescencia , Células HeLa , Humanos , Microscopía Confocal , Modelos Moleculares
5.
bioRxiv ; 2024 Feb 02.
Artículo en Inglés | MEDLINE | ID: mdl-38352588

RESUMEN

Complex carbohydrates called glycans play crucial roles in the regulation of cell and tissue physiology, but how glycans map to nanoscale anatomical features must still be resolved. Here, we present the first nanoscale map of mucin-type O -glycans throughout the entirety of the Caenorhabditis elegans model organism. We construct a library of multifunctional linkers to probe and anchor metabolically labelled glycans in expansion microscopy (ExM), an imaging modality that overcomes the diffraction limit of conventional optical microscopes through the physical expansion of samples embedded in a polyelectrolyte gel matrix. A flexible strategy is demonstrated for the chemical synthesis of linkers with a broad inventory of bio-orthogonal functional groups, fluorophores, anchorage chemistries, and linker arms. Employing C. elegans as a test bed, we resolve metabolically labelled O -glycans on the gut microvilli and other nanoscale anatomical features using our ExM reagents and optimized protocols. We use transmission electron microscopy images of C. elegans nano-anatomy as ground truth data to validate the fidelity and isotropy of gel expansion. We construct whole organism maps of C. elegans O -glycosylation in the first larval stage and identify O -glycan "hotspots" in unexpected anatomical locations, including the body wall furrows. Beyond C. elegans , we provide validated ExM protocols for nanoscale imaging of metabolically labelled glycans on cultured mammalian cells. Together, our results suggest the broad applicability of the multifunctional reagents for imaging glycans and other metabolically labelled biomolecules at enhanced resolutions with ExM.

6.
Cell Chem Biol ; 26(12): 1643-1651.e4, 2019 Dec 19.
Artículo en Inglés | MEDLINE | ID: mdl-31604616

RESUMEN

Degradable crosslinkers that respond to intracellular biological stimuli are a critical component of many drug delivery systems. With numerous stimuli-responsive drug delivery systems in development, it is important to quantitatively study their intracellular processing. Herein we report a framework for quantifying the rate of intracellular bond degradation in the endocytic pathway. Toward this end, we devised and synthesized a reduction-sensitive FRET-based crosslinker that can be readily conjugated to a variety of targeting ligands. This crosslinker was conjugated to trastuzumab, a humanized monoclonal antibody against the HER2 receptor. We developed a model based on mass-action kinetics to describe the intracellular processing of this conjugate. The kinetic model was developed in conjunction with live-cell experiments to extract the rate constant for intracellular disulfide bond degradation. This framework may be applied to other endocytosis pathways, bond types, and cell types to quantify this fundamental degradation rate parameter.


Asunto(s)
Inmunoconjugados/metabolismo , Trastuzumab/metabolismo , Compuestos de Boro/química , Compuestos de Boro/metabolismo , Línea Celular Tumoral , Disulfuros/química , Disulfuros/metabolismo , Transferencia Resonante de Energía de Fluorescencia , Glutatión/química , Semivida , Humanos , Inmunoconjugados/inmunología , Cinética , Microscopía Confocal , Modelos Teóricos , Receptor ErbB-2/inmunología , Rodaminas/química , Rodaminas/metabolismo , Transglutaminasas/metabolismo , Trastuzumab/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA